Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema
- PMID: 24332536
- PMCID: PMC3946576
- DOI: 10.1016/j.ophtha.2013.09.023
Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema
Abstract
Purpose: Among cases of visually significant uveitic macular edema (ME), to estimate the incidence of visual improvement and identify predictive factors.
Design: Retrospective cohort study.
Participants: Eyes with uveitis, seen at 5 academic ocular inflammation centers in the United States, for which ME was documented to be currently present and the principal cause of reduced visual acuity (<20/40).
Methods: Data were obtained by standardized chart review.
Main outcome measures: Decrease of ≥ 0.2 base 10 logarithm of visual acuity decimal fraction-equivalent; risk factors for such visual improvement.
Results: We identified 1510 eyes (of 1077 patients) with visual impairment to a level <20/40 attributed to ME. Most patients were female (67%) and white (76%), and had bilateral uveitis (82%). The estimated 6-month incidence of ≥ 2 lines of visual acuity improvement in affected eyes was 52% (95% confidence interval [CI], 49%-55%). Vision reduced by ME was more likely to improve by 2 lines in eyes initially with poor visual acuity (≤ 20/200; adjusted hazard ratio [HR] 1.5; 95% CI, 1.3-1.7), active uveitis (HR, 1.3; 95% CI, 1.1-1.5), and anterior uveitis as opposed to intermediate (HR, 1.2), posterior (HR, 1.3), or panuveitis (HR, 1.4; overall P = 0.02). During follow-up, reductions in anterior chamber or vitreous cellular activity or in vitreous haze each led to significant improvements in visual outcome (P <0.001 for each). Conversely, snowbanking (HR, 0.7; 95% CI, 0.4-0.99), posterior synechiae (HR, 0.8; 95% CI, 0.6-0.9), and hypotony (HR, 0.2; 95% CI, 0.06-0.5) each were associated with lower incidence of visual improvement with respect to eyes lacking each of these attributes at a given visit.
Conclusions: These results suggest that many, but not all, patients with ME causing low vision in a tertiary care setting will enjoy meaningful visual recovery in response to treatment. Evidence of significant ocular damage from inflammation (posterior synechiae and hypotony) portends a lower incidence of visual recovery. Better control of anterior chamber or vitreous activity is associated with a greater incidence of visual improvement, supporting an aggressive anti-inflammatory treatment approach for ME cases with active inflammation.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Figures




Similar articles
-
Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.Ophthalmology. 2021 May;128(5):719-728. doi: 10.1016/j.ophtha.2020.08.035. Epub 2020 Sep 10. Ophthalmology. 2021. PMID: 32918964 Free PMC article. Clinical Trial.
-
Hypopyon in patients with uveitis.Ophthalmology. 2010 Feb;117(2):366-72. doi: 10.1016/j.ophtha.2009.07.025. Epub 2009 Dec 14. Ophthalmology. 2010. PMID: 20006905 Free PMC article.
-
TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.Retina. 2018 Jul;38(7):1361-1370. doi: 10.1097/IAE.0000000000001690. Retina. 2018. PMID: 28520640
-
Macular edema in uveitis.Folia Med (Plovdiv). 2012 Jul-Sep;54(3):14-21. doi: 10.2478/v10153-011-0092-8. Folia Med (Plovdiv). 2012. PMID: 23270202 Review.
-
Epidemiology of Macular Edema in Uveitis.Ocul Immunol Inflamm. 2019;27(2):169-180. doi: 10.1080/09273948.2019.1576910. Epub 2019 Mar 1. Ocul Immunol Inflamm. 2019. PMID: 30821631 Review.
Cited by
-
Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema.Front Immunol. 2020 Sep 25;11:579005. doi: 10.3389/fimmu.2020.579005. eCollection 2020. Front Immunol. 2020. PMID: 33101305 Free PMC article.
-
Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.Clin Ophthalmol. 2019 Sep 10;13:1761-1777. doi: 10.2147/OPTH.S180580. eCollection 2019. Clin Ophthalmol. 2019. PMID: 31571815 Free PMC article. Review.
-
Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis.PLoS One. 2019 Jan 24;14(1):e0210799. doi: 10.1371/journal.pone.0210799. eCollection 2019. PLoS One. 2019. PMID: 30677041 Free PMC article.
-
Single Low-dose Suprachoroidal Triamcinolone Acetonide Injection in Macular Edema Secondary to Noninfectious Posterior Uveitis.Middle East Afr J Ophthalmol. 2024 Jan 22;30(1):6-12. doi: 10.4103/meajo.meajo_78_21. eCollection 2023 Jan-Mar. Middle East Afr J Ophthalmol. 2024. PMID: 38435103 Free PMC article.
-
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7. Ophthalmology. 2015. PMID: 26359188 Free PMC article. Clinical Trial.
References
-
- Lardenoye CW, van Kooji B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446–9. - PubMed
-
- Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818–24. - PubMed
-
- Yanoff M, Fine BS, Brucker AJ, Eagle RC., Jr Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28(suppl):505–11. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources